Get the Stockscreener App
1.53
25.18%
-0.515
After Hours:
1.57
0.04
+2.61%
Kala Bio Inc stock is traded at $1.53, with a volume of 4.83M.
It is down -25.18% in the last 24 hours and down -86.36% over the past month.
Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.
See More
Previous Close:
$2.045
Open:
$1.78
24h Volume:
4.83M
Relative Volume:
5.87
Market Cap:
$10.74M
Revenue:
$5.75M
Net Income/Loss:
$-38.96M
P/E Ratio:
-0.1227
EPS:
-12.47
Net Cash Flow:
$-32.63M
1W Performance:
-90.95%
1M Performance:
-86.36%
6M Performance:
-73.30%
1Y Performance:
-73.16%
1-Day Range:
$1.50
$1.95
1-Week Range:
$1.10
$19.77
52-Week Range:
$1.10
$20.60
Kala Bio Inc Stock (KALA) Company Profile
Name
Kala Bio Inc
Sector
Industry
Phone
781-996-5252
Address
1167 MASSACHUSETTS AVENUE, ARLINGTON, MA
Compare KALA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KALA
Kala Bio Inc
|
1.53 | 14.36M | 5.75M | -38.96M | -32.63M | -12.47 |
|
VRTX
Vertex Pharmaceuticals Inc
|
391.64 | 101.35B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.00 | 58.66B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
562.27 | 59.43B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
737.56 | 44.01B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
340.70 | 36.56B | 3.81B | -644.79M | -669.77M | -6.24 |
Kala Bio Inc Stock (KALA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-30-25 | Downgrade | Mizuho | Outperform → Neutral |
| Sep-29-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Sep-29-25 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Sep-08-25 | Initiated | Mizuho | Outperform |
| Jul-11-25 | Initiated | Ladenburg Thalmann | Buy |
| Mar-30-22 | Downgrade | JP Morgan | Neutral → Underweight |
| Aug-06-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-14-20 | Downgrade | Jefferies | Buy → Hold |
| Jul-23-20 | Initiated | Northland Capital | Outperform |
| Jun-01-20 | Resumed | Oppenheimer | Outperform |
| May-27-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-09-20 | Upgrade | BofA/Merrill | Neutral → Buy |
| Dec-17-19 | Downgrade | BofA/Merrill | Buy → Neutral |
| Mar-14-19 | Initiated | Jefferies | Buy |
View All
Kala Bio Inc Stock (KALA) Latest News
KALA BIO, Inc. Securities Lawsuit Investigation - Claim Depot
Kala Bio Shares Fall After Downgrade From Mizuho - MarketScreener
A Heavy Trading Day Sends Biotech And Finance Stocks Reeling - Finimize
Kala Bio Faces Diminishing Options After Eye Drug Failure - insights.citeline.com
Mizuho Downgrades KALA BIO to Neutral From Outperform, Price Target is $1.50 - MarketScreener
Kala Bio tanks on Phase IIb KPI-012 miss - The Pharma Letter
KALA BIO (NASDAQ:KALA) Downgraded to Hold Rating by Lifesci Capital - MarketBeat
Forecasting KALA BIO Inc. price range with options dataJuly 2025 Movers & High Yield Equity Trading Tips - newser.com
Kala Bio Halts Eye Drug Development After Phase 2b Trial Failure - Medical Dialogues
Is KALA BIO Inc. meeting your algorithmic filter criteriaJuly 2025 Market Mood & Reliable Entry Point Alerts - newser.com
Electronic Arts, Kala Bio, Semtech - TradingView
KALA BIO (KALA) Price Target Increased by 23.00% to 31.36 - Nasdaq
KALA BIO (NASDAQ:KALA) Receives “Neutral” Rating from HC Wainwright - Defense World
Can KALA BIO Inc. stock surprise with earnings upsideJuly 2025 Closing Moves & Daily Profit Maximizing Trade Tips - newser.com
Is KALA BIO Inc. stock supported by strong cash flowsTrade Exit Summary & Reliable Price Breakout Alerts - newser.com
Quantitative breakdown of KALA BIO Inc. recent moveWeekly Trend Report & Safe Entry Point Identification - newser.com
Market Today: EA's Historic LBO and KALA BIO's Plunge - GuruFocus
KALA BIO Announces Topline Results from CHASE Phase 2b - GlobeNewswire
Biotech company to lay off half its workforce after eye drug fails trial - The Business Journals
KalaBio (KALA) Halts KPI-012 Development After Disappointing Tri - GuruFocus
HC Wainwright Downgrades KALA BIO to Neutral From Buy; Shares Plunge - MarketScreener
Crude Oil Falls Sharply; Carnival Posts Upbeat Earnings - Benzinga
Kala Bio stock plunges after failed Phase 2b trial for eye treatment - Investing.com
KALA Stock Falls Sharply After KPI-012 Clinical Trial Disappointment - GuruFocus
Arlington biotech slashes workforce in half after trial failure - The Business Journals
Why Is Eye Disease Focused Kala Bio Stock Plunging On Monday? - Benzinga
Kala Bio Stock Just Plunged 92% Today – Here’s What Happened - Asianet Newsable
KALA Bio (KALA) Stock Plummets 92% After Failed Trial - GuruFocus
Nasdaq Jumps 150 Points; US Pending Home Sales Rise - Benzinga
KALA Bio's KPI-012 Fails Phase 2b CHASE Study; Shares Plunge Over 90% In Pre-Market - Nasdaq
KALA's Phase 2b Trial of KPI-012 Falls Short of Key Milestones - GuruFocus
KALA BIO plunges 92% after phase 2 failure of eye condition drug - Seeking Alpha
Kala Pharmaceuticals Halts KPI-012 Development After Trial Failure - TipRanks
Kala Bio’s corneal treatment fails to meet primary endpoint in trial - Investing.com
Kala Bio plunges after scrapping development of lead drug - MarketScreener
Kala Bio announces topline results from Chase phase 2b clinical trial - MarketScreener
KALA BIO scraps development of eye disease drug after trial failure - MarketScreener
KALA BIO Announces Topline Results from CHASE Phase 2b Clinical Trial Evaluating KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED) Did Not Meet Primary Endpoint - Yahoo Finance
Candlestick signals on KALA BIO Inc. stock today2025 Bull vs Bear & Momentum Based Trading Signals - newser.com
Kala Bio Inc Stock (KALA) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.36%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):